Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 8/20 | 0.42 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 3/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4951166 | 1.00 | KMT2A (0.44) | KMT2AMEN1NAA50RENNTSR2 | |
| SCHEMBL30051327 | 0.86 | KMT2A (0.56) | KMT2AMEN1REN | |
| SCHEMBL30051232 | 0.85 | KMT2A (0.51) | KMT2AMEN1RENNTSR2 | |
| SCHEMBL4946515 | 0.84 | GRB2 (0.47) | NAA50NTSR2CXCL8NTSR1 | |
| SCHEMBL4946505 | 0.84 | GRB2 (0.47) | NAA50NTSR2CXCL8NTSR1 | |
| SCHEMBL30066756 | 0.84 | NTSR2 (0.46) | KMT2ARENNTSR2NTSR1 | |
| SCHEMBL29438447 | 0.83 | DPP4 (0.43) | KMT2AMEN1REN | |
| SCHEMBL30051566 | 0.82 | MEN1 (0.58) | KMT2AMEN1RENCTSDBACE1 | |
| SCHEMBL30930555 | 0.82 | CXCL8 (0.49) | RENCXCL8NTSR1 | |
| SCHEMBL30574235 | 0.81 | DPP4 (0.42) | KMT2AMEN1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470776-B2 | Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2008-12-30 | — | — | US | disclosed |
| US-20070167356-A1 | Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof | CUMMINGS RICHARD D | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167356-A1 | Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof | SIGLEC7, SIGLEC9, SELL | KMT2A 4023/4885MEN1 4852/4885NAA50 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.